ABX464 clinical trials

Studies by the year they started

21 studies that test it; most in 2019 (3)

Who runs them

Industry 21 · Other 0

Abivax S.A. (21)

Often tested with

Tested in the same studies.

Caffeine (1) · Fluvoxamine (1)

Studies

Open first, then newest update. How each study uses ABX464 is read from its arms, and is right about nine times in ten.

Testing it · 21

• Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's DiseaseRecruitingPhase 2Abivax S.A.NCT06456593Written as Obefazimod
• Study to Evaluate Pharmacokinetics, Relative Bioavailability, Palatability of Obefazimod Minitablet FormulationRecruitingPhase 1Abivax S.A.NCT07453784Written as Obefazimod 50 mg Capsule
• ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2CompletedPhase 3Abivax S.A.NCT05507216Written as ABX464
• ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1CompletedPhase 3Abivax S.A.NCT05507203Written as ABX464
• ABTECT - MaintenanceActive, not recruitingPhase 3Abivax S.A.NCT05535946Written as ABX464
• Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative ColitisCompletedPhase 2Abivax S.A.NCT04023396Written as ABX464
• Long-term Safety and Efficacy Profile of ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisActive, not recruitingPhase 2Abivax S.A.NCT05177835Written as ABX464
• Dose-Ranging Phase 2b Study of ABX464 in Moderate to Severe Ulcerative ColitisCompletedPhase 2Abivax S.A.NCT03760003Written as ABX464 100 mg
• ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19TerminatedPhase 2/3Abivax S.A.NCT04393038Written as ABX464
• Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid ArthritisCompletedPhase 2Abivax S.A.NCT04049448Written as ABX464
• Study Evaluating the Long-term Safety and Efficacy of ABX464 in Active Ulcerative ColitisCompletedPhase 2Abivax S.A.NCT03368118Written as ABX464
• ABX464 in Fully Controlled HIV Infected Patients Treated With Boosted Protease Inhibitor TreatmentCompletedPhase 2Abivax S.A.NCT02735863Written as ABX464
• Phase 2b/3 Study of ABX464 in Moderate to Severe Active Crohn's Disease PatientsWithdrawnPhase 2/3Abivax S.A.NCT03905109Written as ABX464
• ABX464 in Subjects With Moderate to Severe Active Ulcerative ColitisCompletedPhase 2Abivax S.A.NCT03093259Written as ABX464
• ABX464 First in Man StudyCompletedPhase 1Abivax S.A.NCT02792686Written as ABX464
• A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive AdultsCompletedPhase 1/2Abivax S.A.NCT02990325Written as ABX464 150mg
• Study of Two Doses of ABX464 in Participants With Moderate to Severe Rheumatoid ArthritisCompletedPhase 2Abivax S.A.NCT03813199Written as ABX464 50mg
• Safety and Pharmacokinetics Study in Healthy Japanese VolunteersCompletedPhase 1Abivax S.A.NCT05032560Written as ABX464
• Evaluation of the Potential CYP1A2-mediated Drug Drug Interaction Safety, and Tolerability of ABX464CompletedPhase 1Abivax S.A.NCT05121714Written as ABX464
• Safety, PK and PD Study of ABX464 in Untreated HIV PatientsCompletedPhase 2Abivax S.A.NCT02452242Written as ABX464

See all 21 studies that test ABX464 →

Codes

What other systems call ABX464 · ClinicalTrials.gg INT000790

• MeSH (NLM) C000623073ABX464One source ClinicalTrials.gov

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.